Organovo Holdings Inc. articles
Publication Summary:
Recent advances in the directed differentiation of human pluripotent stem cells to kidney organoids advances the prospect of drug screening, disease modelling, and even restoration of renal function using patient-derived stem cell lines. Here, we demonstrate the successful adaptation of our directed differentiation protocol to the NovoGen Bioprinter® MMX technology to achieve automated, rapid fabrication of self-organizing kidney organoids. Bi
Publication Summary:
The identification of targets and biomarkers and development of therapeutics for nonalcoholic fatty liver disease (NAFLD) may be accelerated by the use of well-characterized primary cell and tissue reagents, as well as improved in vitro human cell-based disease models, including three-dimensional (3D) bioprinted liver tissue. The characteristics of donors from which the cells are isolated, and especially their stage on the NAFLD continuum
Publication Summary:
The growing global incidence of NASH mirrors the availability of nutrients. Over-nutrition also results in insulin resistance and type-2 diabetes, which are often co-morbidities associated with NASH and are known to drive more adverse outcomes. MSDC-0602K, a modulator of the mitochondrial pyruvate carrier (MPC), is in clinical trials as a potential treatment for NASH. Preclinical studies have shown that the mitochondrial pyruvate carrier is increa
Publication Summary:
Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterized by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognized as the most common cause of chronic liver disease in the western world, with an estimated prevalence of 25% worldwide, and is projected to become the lead
Publication Summary:
Compound induced chronic liver injury can lead to initiation of profibrotic processes resulting in sustained production of growth factors and profibrotic cytokines where inflammation, tissue remodeling and repair pathways are activated simultaneously to counteract the injury. Evaluation of potential antifibrotic therapies are limited using conventional non-human animal models, due to their inability to accurately reflect complex in vivo h